Most of the approved drugs for patients with metastatic prostate cancer include immunotherapy, hormonal therapy, and chemotherapy. Precision medicine is the ability to use biomarkers for the optimal therapy, which makes treatment decisions easier for these patients, states Armstrong.

A blood test called the AR-V7 assay can help determine which patients will become resistant to enzalutamide (Xtandi) or abiraterone acetate (Zytiga), explains Armstrong.

Most of the approved drugs for patients with metastatic prostate cancer include immunotherapy, hormonal therapy, and chemotherapy. Precision medicine is the ability to use biomarkers for the optimal therapy, which makes treatment decisions easier for these patients, states Armstrong.

A blood test called the AR-V7 assay can help determine which patients will become resistant to enzalutamide (Xtandi) or abiraterone acetate (Zytiga), explains Armstrong.